'Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption'

Aging Cell

Volumn 13, Issue 1, 2014, Pages 102-110

  De Lorenzo, Mariana S ^a   Chen, Wen ^b   Baljinnyam, Erdene ^a   Carlini, María J ^c   La Perle, Krista ^d   Bishop, Sanford P ^a   Wagner, Thomas E ^b   Rabson, Arnold B ^e   Vatner, Dorothy E ^a   Puricelli, Lydia I ^c   Vatner, Stephen F ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b CLEMSON UNIVERSITY   (United States)

^c Instituto de Oncologia Angel H Roffo   (Argentina)

^d OHIO STATE UNIVERSITY   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

AC5 inhibitor; Adenylyl cyclase (AC) knockout mice; Angiogenesis; B16F10 melanoma; LP07 lung adenocarcinoma; MMTV HER 2 neu mice; Tumor protection

Indexed keywords

ADENYLATE CYCLASE; ADENYLYL CYCLASE TYPE 5 PROTEIN; ANTINEOPLASTIC AGENT; CARBOXYMETHYLCELLULOSE; UNCLASSIFIED DRUG; VIDARABINE; ADENYLYL CYCLASE TYPE V; ENZYME INHIBITOR;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; GENE DISRUPTION; HUMAN; HUMAN CELL; LONGEVITY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; GENE DELETION; GENETICS; KNOCKOUT MOUSE; MELANOMA; METABOLISM; PATHOLOGY;

MOUSE MAMMARY TUMOR VIRUS; MUS;

ADENYLATE CYCLASE; ANIMALS; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; GENE DELETION; LONGEVITY; MELANOMA; MICE; MICE, KNOCKOUT;

EID: 84892497342     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12152     Document Type: Article

References (34)

1. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK (2013) Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat. Commun. 4, 1403. doi:10.1038/ncomms2413.
2. Bos JL (2003) Epac: a new cAMP target and new avenue in cAMP research. Nat. Rev. Mol. Cell Biol. 4, 733-738.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348, 1625-1638.
4. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE (2000) The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19, 968-988.
5. 2)/EP4 receptor signaling pathway in colon cancer cells. Cancer Biol. Ther. 10, 1056-1066.
6. Chrisp CE, Turke P, Luciano A, Swalwell S, Peterson J, Miller RA (1996) Lifespan and lesions in genetically heterogeneous (four-way cross) mice: a new model for aging research. Vet. Pathol. 33, 735-743.
7. De Clercq E (1993) Antivirals for the treatment of herpes virus infections. J. Antimicrob. Chemother. 32, 121-132.
8. De Lorenzo MS, Ripoll GV, Yoshiji H, Yamazaki M, Thorgeirsson UP, Alonso DF, Gomez DE (2003) Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo 17, 45-50.
9. De Lorenzo MS, Farina HG, Alonso DF, Gomez DE (2004) Role of protein kinase C-dependent signaling pathways in the antiangiogenic properties of nafoxidine. Anticancer Res. 24, 1737-1743.
10. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzua P, Vatner SF, Rabson AB (2011) Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 32, 1381-1387.
11. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57-70.
12. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
13. Hu CL, Chandra R, Ge H, Pain J, Yan L, Babu G, Depre C, Iwatsubo K, Ishikawa Y, Sadoshima J, Vatner SF, Vatner DE (2009) Adenylyl cyclase type 5 protein expression during cardiac development and stress. Am. J. Physiol. Heart Circ. Physiol. 297, H1776-H1782.
14. Iwatsubo K, Bravo C, Uechi M, Baljinnyam E, Nakamura T, Umemura M, Lai L, Gao S, Yan L, Zhao X, Park M, Qiu H, Okumura S, Iwatsubo M, Vatner DE, Vatner SF, Ishikawa Y (2012) Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase. Am. J. Physiol. Heart Circ. Physiol. 302, H2622-H2628.
15. Jacquemart IC, Springs AE, Chen WY (2009) Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Int. J. Oncol. 34, 517-528.
16. Ji Y, Chen S, Xiao X, Zheng S, Li K (2012) β-blockers: a novel class of antitumor agents. Onco. Targets Ther. 5, 391-401.
17. Knight JA (2011) Diseases and disorders associated with excess body weight. Ann. Clin. Lab. Sci. 41, 107-121.
18. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD, Carter JS, de Coronado S, Downing JR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Hiai H, Jaffe ES, MacLennan IC, Pandolfi PP, Pattengale PK, Perkins AS, Simpson RM, Tuttle MS, Wong JF, Morse HC 3rd, Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium (2002) Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100, 238-245.
19. Merkle D, Hoffmann R (2011) Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell. Signal. 23, 507-515.
20. Patel TB, Du Z, Pierre S, Cartin L, Scholich K (2001) Molecular biological approaches to unravel adenylyl cyclase signaling and function. Gene 269, 13-25.
21. Peluffo GD, Stillitani I, Rodriguez VA, Diament MJ, Klein SM (2004) Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int. J. Cancer 110, 825-830.
22. Plunkett W, Lapi L, Ortiz PJ, Cohen SS (1974) Penetration of mouse fibroblasts by the 5′-phosphate of 9-beta-D-arabinofuranosyladenine and incorporation of the nucleotide into DNA. Proc. Natl Acad. Sci. USA 71, 73-77.
23. Sakamoto KM, Frank DA (2009) CREBin the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin. Cancer Res. 15, 2583-2587.
24. Schmidt CM, Mckillop IH, Cahill PA, Sitzmann JV (1999) The role of cyclic AMP p42/44MAPK signaling in the regulation of human hepatocellular carcinoma growth. Eur. J. Gastroenterol. Hepatol. 11, 1393-1399.
25. Shikata K, Ninomiya T, Kiyohara Y (2013) Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 104, 9-14.
26. Storer JB (1966) Longevity and gross pathology at death in 22 inbred mouse strains. J. Gerontol. 21, 404-409.
27. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ (2006) HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res. 66, 5504-5511.
28. Urtreger AJ, Diament MJ, Ranuncolo SM, Vidal MC, Puricelli LI, Klein SM, Bal de Kier Joffe ED (2001) New murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndrome. Int. J. Oncol. 18, 639-647.
29. Vatner SF, Park M, Yan L, Lee GJ, Lai L, Iwatsubo K, Ishikawa Y, Pessin J, Vatner DE (2013) Adenylyl cyclase type 5 in cardiac disease, metabolism and aging. Am. J. Physiol. Heart Circ. Physiol. 305, H1-8. doi:10.1152/ajpheart.00080.2013
30. Willoughby D, Cooper DM (2007) Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol. Rev. 87, 965-1010.
31. Wolf NS, Giddens WE, Martin GM (1988) Life table analysis and pathologic observations in male mice of a long-lived hybrid strain (Af X C57BL/6) F1. J. Gerontol. 43, B71-B78.
32. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W, Hirotani S, Ishikawa Y, Sadoshima J, Vatner SF (2007) Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130, 247-258.
33. Yan L, Park JY, Dillinger JG, De Lorenzo MS, Yuan C, Lai L, Wang C, Ho D, Tian B, Stanley WC, Auwerx J, Vatner DE, Vatner SF (2012) Common mechanisms for calorie restriction and adenylyl cyclase type 5 knockout models of longevity. Aging Cell 11, 1110-1120.
34. Yano Y, Kamma H, Matsumoto H, Fujiwara M, Bando H, Hara H, Yashiro T, Ueno E, Ito K, Uchida K (2007) Growth suppression of thyroid cancer cells by adenylcyclase activator. Oncol. Rep. 18, 441-445.